MDMA-Assisted Therapy
Core Mechanism
MDMA reduces fear response and increases trust/empathy, enabling deeper trauma processing within therapeutic relationship
Ontology
PTSD maintained by overwhelming fear that prevents therapeutic engagement; MDMA lowers this barrier pharmacologically
Therapeutic Voice
"You're safe here. If something difficult comes up, you can move toward it — you don't have to do this alone."
View of the Person
A traumatized being whose fear barriers to therapeutic engagement can be pharmacologically lowered to enable processing
Evidence
FDA declined approval (2024) citing methodology; not currently approved
Phase 3 trials (Mitchell et al., 2021, 2023)
Phase 3 data analyzed
Phase 3 showed large effects. FDA advisory committee voted against approval Aug 2024 — functional unblinding and data concerns. Regulatory status unresolved.
Conditions
Epistemology
Blind Spots
FDA declined approval (2024); methodological concerns about unblinding; not currently legally available outside research
Contraindications
Cardiovascular conditions (uncontrolled hypertension, arrhythmias), hepatic impairment, current use of MAOIs or SSRIs, active psychosis or psychotic spectrum disorders, seizure disorders, pregnancy
Training
Not FDA-approved (2025). MAPS Training for research/expanded access. Co-therapist model
MAPS training program; regulatory evolving
Core: 80-120 hrs + supervised sessions
$5K-10K
Equity & Cultural Adaptations
Philosophical Roots
Mithoefer (inner healing intelligence); Rogers (organismic wisdom, given conditions); Buber (I-Thou enabled pharmacologically); trauma processing theory
Related Modalities
Controversies & Ethical Concerns
FDA declined approval Aug 2024 (methodological concerns, unblinding, data integrity). Regulatory future uncertain
The FDA declined to approve MDMA-assisted therapy for PTSD, citing trial design concerns, potential for bias, and safety risks. An advisory committee voted 9-2 against approval. Concerns included misconduct allegations during trials and blinding integrity questions.
MAPS expressed disappointment and stated it would work with FDA on a path forward. Supporters argue the FDA applied unusually stringent standards compared to other psychiatric medications.
Former trial participant Meaghan Buisson alleged inappropriate touch by therapists Richard Yensen and Donna Dryer during MDMA sessions. Allegations featured in the podcast Cover Story: Power Trip. Yensen’s license was subsequently surrendered.
MAPS acknowledged the allegations and published a Code of Ethics. Critics noted the Code’s promise to ‘never abandon a participant’ contradicted reported experiences of complainants.
Test Yourself
Why co-therapists?
Show answer
Two therapists provide containment during 6-8 hour sessions, model healthy relating.